Author Interviews, Diabetes, Kidney Disease, Nature, Semaglutide / 31.10.2024

MedicalResearch.com Interview on publication of: Prof. dr. H.J. (Hiddo) Lambers Heerspink Clinical Pharmacologist Faculty of Medical Sciences University of Groningen MedicalResearch.com: What is the background for this study? What are the main findings? Response: The diabetes drug semaglutide, also known as Ozempic, has a positive effect for patients with chronic kidney damage and obesity. The amount of protein in their urine decreased, as did the degree of inflammation of their kidneys and their blood pressure. Hiddo L. Heerspink got the idea for this study at the beginning of the corona pandemic. Earlier, he had discovered that another class of drugs against diabetes-2, the so-called SGLT2 inhibitors also appeared to work well for patients with chronic kidney damage without diabetes. He therefore wanted to investigate whether semaglutide would also work positively for patients with chronic kidney disease and obesity. (more…)
Semaglutide, Weight Research / 19.10.2024

In recent years, injectable weight loss medications have surged in popularity, becoming a preferred choice for individuals seeking effective and sustainable weight management solutions. This trend is driven by advancements in medical science, increased awareness of obesity-related health risks, and the convenience offered by online healthcare platforms. Among the various options available, medications like semaglutide and tirzepatide have gained significant attention for their efficacy in promoting weight loss.

Understanding Injectable Weight Loss Medications

Injectable weight loss medications are typically prescribed for individuals struggling with obesity or those who have not achieved desired weight loss results through diet and exercise alone. These medications work by targeting specific hormones and receptors in the body that regulate appetite, metabolism, and fat storage. Unlike oral weight loss pills, injectables often provide more consistent and potent effects, making them a viable option for long-term weight management. (more…)
Semaglutide, Weight Research / 23.09.2024

Ozempic (semaglutide) is a prescription medication designed to help manage type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists, which work by increasing insulin production, reducing blood sugar levels, and slowing digestion to help improve glucose control. Ozempic has also gained attention for its potential role in weight management, but its primary use is for patients with type 2 diabetes who need help controlling their blood sugar. ozempic-weightloss To get the best results from Ozempic, following the correct dosing schedule is critical. A structured approach to dosage allows the body to adjust to the medication, reduces the likelihood of side effects, and ensures that patients achieve optimal blood glucose control over time. Many people also explore options to buy Ozempic from Canada as a way to save on costs while maintaining their treatment regimen In this article, you will learn about Ozempic dosing, how to follow the dosing schedule, where to inject, what to do if you miss a dose, and more. Read on to find out how you can also save on Ozempic when you order through BuyCanadianInsulin.com. Editor' note: If you are purchasing Ozempic from Canada, please ensure it is legal where you live and that you are not purchasing a counterfeit product. (more…)
Semaglutide, Weight Research / 18.09.2024

If you’ve been hearing a lot of buzz about the Wegovy pen and are curious about what it can do for weight loss, you're in the right place. There’s a lot to understand, but we’re going to break it down into simple, easy-to-follow information. Whether you're exploring your options or have already made up your mind about giving it a try, here's everything you need to know about the Wegovy pen.

What is the Wegovy Pen?

Let’s start with the basics. The Wegovy pen is a once-weekly injectable medication that’s used to support weight loss in adults. It contains the active ingredient semaglutide, which is designed to help regulate appetite. In simple terms, it helps you feel fuller for longer, so you're less likely to overeat. Semaglutide mimics a hormone called GLP-1 (glucagon-like peptide-1), which plays a role in controlling hunger. By imitating this hormone, Wegovy helps reduce food cravings and manages how much you eat. (more…)
Author Interviews / 17.09.2024

Editor's note: If you purchase semaglutide or similar medications, be sure to be followed by your health care provider and verify that the supplier is reputable before your purchases. When it comes to weight loss, it often feels like everyone has an opinion. Some swear by keto, while others say it's all about intermittent fasting. And let’s not forget the ever-popular crash diets that promise instant results but leave you feeling sluggish and starving. With so much conflicting advice, how can you figure out what actually works? This post attempts to break down the science behind weight loss, cutting through the noise and getting to the core of what really makes a difference in shedding those extra pounds—without the fads. weight-obesity-scale

Calories In, Calories Out: The Basics

At its most fundamental level, weight loss comes down to one basic principle: calories in versus calories out. The idea is simple—if you consume fewer calories than your body needs, you'll lose weight. This is known as creating a calorie deficit. Your body has to find energy somewhere, and when you're not giving it enough through food, it starts to use stored fat. However, it's not always as straightforward as it seems. People have different metabolic rates, meaning some burn calories faster than others. Plus, hormones, genetics, and lifestyle factors can all affect how easy or difficult it is to drop pounds. This is why two people on the same diet might experience different results. Key takeaway: To lose weight, you need to consistently eat fewer calories than you burn. But keep in mind that individual factors can influence how quickly (or slowly) this happens for you. (more…)
Nutrition, Weight Research / 04.09.2024

Semaglutide has emerged as a promising medication for weight loss, offering significant results for many users. Wegovy's semaglutide , a glucagon-like peptide-1 (GLP-1) receptor agonist, works by mimicking a natural hormone that regulates appetite and food intake. Combining semaglutide with healthy lifestyle changes can accelerate weight loss and improve overall outcomes. While semaglutide alone can lead to impressive weight reduction, there are strategies to enhance its effectiveness. Eating a nutritious, low-calorie diet rich in fiber and protein can complement the appetite-suppressing effects of the medication. Regular physical activity further supports weight loss efforts and overall health improvements. It's important to note that the full effects of semaglutide may take several weeks to become noticeable. Patience and consistency are key when using this medication for weight management. As with any weight loss journey, individual results may vary, but many users experience significant reductions in body weight over time.

Key Takeaways

  • Semaglutide mimics GLP-1 to regulate appetite and food intake
  • Combining the medication with a healthy diet and exercise enhances weight loss
  • Consistency and patience are crucial for optimal results with semaglutide
(more…)
Pharmacology, Semaglutide / 11.08.2024

Oral Semaglutide has emerged as a significant advancement in the realm of weight loss treatments. As an alternative to traditional injectable options, oral Semaglutide offers convenience and effectiveness. This guide provides an in-depth look at oral Semaglutide, its benefits, how to access it through prescriptions, and explores compounded semaglutide online.

What is Oral Semaglutide?

Oral Semaglutide is an oral form of the medication Semaglutide, which was originally available only as an injection. It is used to manage weight loss and control blood sugar levels in individuals with obesity or type 2 diabetes.
  • Mechanism of Action: Semaglutide mimics a hormone called GLP-1, which helps regulate appetite and insulin secretion. By enhancing these processes, it can support significant weight loss and better blood sugar control.
  • Approval and Usage: The oral version is approved by the FDA for weight management and is typically prescribed as part of a comprehensive weight loss plan that includes diet and exercise.
(more…)
Weight Research / 10.06.2024

Key Takeaways
  • Personalized weight management is crucial in achieving sustainable results.
  • Combined data from multiple sources enhances personalization.
  • Maintaining a relationship between providers and consumers boosts success rates.
The Need for Personalization in Weight Management Personalized weight management plans are essential in today's health-focused world, and research consistently shows their effectiveness over generic approaches. According to a study by the Centers for Disease Control and Prevention (CDC), customized weight management strategies lead to tremendous long-term success in weight loss. Additionally, platforms like BuildMyBod offer providers a turnkey solution to offer diverse services that cater to personal health needs, showing how personalization is becoming a cornerstone in weight management. (more…)
Author Interviews, Diabetes, Orthopedics, Weight Research / 14.02.2024

MedicalResearch.com Interview with: Matthew Magruder, MD PGY3 Orthopaedic Residency Program Department of Orthopaedic Surgery and Rehabilitation Maimonides Medical Center MedicalResearch.com: What is the background for this study? Response: The prevalence of obesity and diabetes mellitus has reached epidemic proportions. Approximately 37.3 million people in the United States, accounting for 11.3% of the total population, have diabetes, and 100.1 million, or 41.9%, of all US citizens are obese. Furthermore, these numbers are only projected to increase in the coming decades. This is an issue for orthopaedic surgeons because diabetes and obesity have consistently been demonstrated to be risk factors for complications following total joint replacements, especially total hip replacements. Therefore, we are in desperate need of new and more effective tools in mitigating the risk of poor outcomes in our joint replacement patients. Semaglutide, and other GLP-1 agonists, are potentially a new tool that can be used to help decrease the risks following joint replacement surgery. Initially a medication to treat diabetes, semaglutide has recently been approved by the FDA to treat obesity as well, as randomized controlled trials have consistently demonstrated significant weight loss with minimal side effects. The purpose of our study was to see what effect the use of semaglutide had on total hip arthroplasty patient outcomes. (more…)
Alcohol, Author Interviews / 25.09.2023

MedicalResearch.com Interview with: Prof. Elisabet Jerlhag Holm Department of Pharmacology Institute of Neuroscience and Physiology The University of Gothenburg MedicalResearch.com: What is the background for this study? Response: Alcohol use disorder (AUD) is a conditioned associated with morbidity, mortality and costs for society. There are today 4 approved medications, but given the heterogeneity of the disease the efficacy of these is limited and new medications are needed. Peptides of the gut-brain axis, such as GLP-1, have been implied as novel treatment targets. We therefore investigated the effect of an agonist for GLP-1, semaglutide, on alcohol drinking in rodents. (more…)
Author Interviews, Dermatology, Diabetes, Heart Disease, Weight Research / 28.08.2023

MedicalResearch.com Interview with: Dr. Alexis Elias Malavazos Endocrinology Unit Clinical Nutrition and Cardiovascular Prevention Service, IRCCS Policlinico Unit of Radiology, IRCCS Policlinico San Donato, San Donato Milanese, Italy   MedicalResearch.com: What is the background for this study? Response: Psoriasis is a systemic inflammatory disease often associated with obesity and type-2 diabetes (T2D). The inflammatory process of psoriasis can target adipose tissue depots, particularly those surrounding the heart and the coronary arteries, exposing them to an increased risk of cardiovascular disease. (more…)
Author Interviews, Diabetes, Gastrointestinal Disease, Weight Research / 16.05.2021

MedicalResearch.com Interview with: Anna Carolina Hoff, MD Lead researcher on the study Founder and Clinical Director Angioskope Brazil São José dos Campos  MedicalResearch.com: What is the background for this study? Response: Obesity is a chronic disease that has become a global pandemic, and its prevalence continues to increase. Overweight (Body Mass Index (BMI) ≥ 27 kg/m2) and obesity (BMI ≥ 30kg/m2) lead to numerous clinical comorbidities, including metabolic, cardiovascular, oncologic, and mental health disorders. It is challenging to achieve significant and sustained weight loss with diet and lifestyle modification alone. Additionally, a reversal of obesity-related co-morbidities and improvement in quality of life entails a percent total body weight loss (%TBWL) of between 5-10%, which is rarely achieved with medications alone. The Endoscopic Sleeve Gastroplasty (ESG) results in a %TBWL between 14.6%-19.7% at 18-24 months,  and improvements in systolic blood pressure (SBP), HbA1c, and dyslipidemia at 12 months. (more…)